You are here: Industry Insights > XLH

News List

EU approval for self-administered Crysvita pharmatimes
July 21, 2021
Kyowa Kirin has received approval in the EU for the self-administration option of its X-linked hypophosphataemia (XLH) treatment Crysvita.
Positive CHMP opinion for self-administered Crysvita pharmatimes
May 11, 2021
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended Kyowa Kirin’s Crysvita for a new self-administration option to treat the rare metabolic bone disease X-linked hypophosphataemia (XLH).
CHMP backs expanding scope of Kyowa Kirin's Crysvita pharmatimes
July 28, 2020
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expanding approval of Kyowa Kirin's Crysvita (burosumab) to include older adolescents and adults living with X-linked hypophosphataemia (XLH).
XLH patients to get routine access to first new therapy in 30 years pharmatimes
October 11, 2018
For the first time in more than 30 years children and young adults in England and Wales with the rare bone disorder XLH will have access to a new treatment option via the NHS.
NICE u-turn approves funding for rare disease therapy Crysvita pharmatimes
September 14, 2018
The National Institute for Health and Care Excellence (NICE) has changed its position on NHS funding for Kyowa Kirin International’s Crysvita...